You are here
Premier Biomedical, Inc.’s CEO Discusses a Bright Future for His Company and All-Natural Solutions with Uptick Newswire’s Stock Day Podcast
PHOENIX, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Premier Biomedical, Inc. (OTCQB: BIEI) (“Company”) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases. and provide all-natural, 50-state-legal topical pain relief products. CEO and President, William A. Hartman, was welcomed back to Stock Day by Everett Jolly.
Hartman started off by telling Jolly he had a lot to cover in this interview and got right to it.
“We started out as an R & D company developing cures for PTSD, cancer, and a number of other serious diseases in an extracorporeal manner via the use of antibodies,” Hartman explained. “In January of 2017, we developed and began selling topical pain relief products featuring Hemp oil/CBD. We didn’t eliminate our R & D goals, rather, we needed the projected sales and revenue from the hemp oil/CBD business to finance potential future R&D efforts. What we have come to realize is that the hemp oil/CBD business is very attractive and offers tremendous growth potential for the near future, particularly as an alternative to dangerous and addictive opioid pain killers.”
Hartman went on to say Premier Biomedical’s hemp oil/CBD products are leaders in the industry. He then turned the discussion to a recent attempted joint venture in Europe. He said Premier Biomedical, Inc. is still in negotiations with the target company; however, that company ended up selling a portion of their business assets to another company. Premier Biomedical, Inc. is now renegotiating terms of that venture as well as actively seeking potential alternative JV targets.
Hartman then turned the conversation to potential Department of Defense sales and mentioned that their program efforts are still in progress. “Our sales team consists of ex-pharmacy people and ex-Purchasing people from the DOD. Our team of experts know all the DOD Purchasing people by their first names,” he said. “Our focus with the DOD as well as with all other governmental agencies is the opioid crisis. Premier Biomedical’s topical pain relief products are an effective alternative to dangerous and addictive pain pills, which are a major contributor to the 200 drug overdose deaths per day occurring in the USA.
“Our sales team is also working with long term care facilities with our topical pain relief products. The passage of Senate Bill # S-2667, The Hemp Farming Act of 2018, is expected to drastically accelerate the sales of hemp oil/CBD pain relief products. It will make clear that CBD is completely legal and is a valid treatment for certain medical conditions.
“We expect that will cause the sales of our CBD products to skyrocket. At the request of the DOD, we developed a two-page summary explaining why CBD versus opioids for pain is preferable and why Premier Biomedical’s topical products are better than the competition.”
He also mentioned they are focused on expanding their web site sales by working with several potential distributors, including a large pharmaceutical service distributor and a convenience store and travel store distributor who want an entire new line of low-cost price-leader products.
“We see a bright future for Premier Biomedical because we have two issued patents on the use of antibodies to combat diseases extra-corporeally without dangerous drug side effects,” Hartman explained. “We also have an issued patent on a drug we named Feldetrex®, in honor of the inventor and our company co-founder, Dr. Mitchell Felder. This drug has multiple potential usages in drug and chemical addiction as well as other potential medical applications, particularly when used in conjunction with cannabinoids. The world is seeking an all-natural and non-addictive alternative to opioid pain products, and we are that alternative.”
To listen to the entire interview with William Hartman, follow this link: https://upticknewswire.com/featured-interview-ceo-william-hartman-of-premier-biomedical-inc-otcqb-biei-11/
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/